Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unprecedented selectivity for homologous lectin targets, differential targeting of the viral receptors L-SIGN and DC-SIGN

  • Delaunay, Clara
  • Pollastri, Sara
  • Thepaut, Michel
  • Cavazzoli, Gianluca
  • Belvisi, Laura
  • Bouchikri, Clementine
  • Labiod, Nuria
  • Lasala, Fatima
  • Gimeno, Ana
  • Franconetti, Antonio|||0000-0002-7972-8795
  • Jiménez Barbero, Jesús|||0000-0001-5421-8513
  • Arda, Ana
  • Delgado, Rafael
  • Bernardi, Anna
  • Fieschi, Franck
DC-SIGN (CD209) and L-SIGN (CD209L) are two C-type lectin receptors (CLRs) that facilitate SARS-CoV-2 infections as viral co-receptors. SARS-CoV-2 manipulates both DC-SIGN and L-SIGN for enhanced infection, leading to interest in developing receptor antagonists. Despite their structural similarity (82% sequence identity), they function differently. DC-SIGN, found in dendritic cells, shapes the immune response by recognizing pathogen-associated carbohydrate patterns. In contrast, L-SIGN, expressed in airway epithelial endothelial cells, is not directly involved in immunity. COVID-19's primary threat is the hyperactivation of the immune system, potentially reinforced if DC-SIGN engages with exogenous ligands. Therefore, L-SIGN, co-localized with ACE2-expressing cells in the respiratory tract, is a more suitable target for anti-adhesion therapy. However, designing a selective ligand for L-SIGN is challenging due to the high sequence identity of the Carbohydrate Recognition Domains (CRDs) of the two lectins. We here present Man84, a mannose ring modified with a methylene guanidine triazole at position 2. It binds L-SIGN with a KD of 12.7μM ± 1 μM (ITC) and is the first known L-SIGN selective ligand, showing 50-fold selectivity over DC-SIGN (SPR). The X-ray structure of the L-SIGN CRD/Man84 complex reveals the guanidinium group's role in achieving steric and electrostatic complementarity with L-SIGN. This allows us to trace the source of selectivity to a single amino acid difference between the two CRDs. NMR analysis confirms the binding mode in solution, highlighting Man84's conformational selection upon complex formation. Dimeric versions of Man84 achieve additional selectivity and avidity in the low nanomolar range. These compounds selectively inhibit L-SIGN dependent trans-infection by SARS-CoV-2 and Ebola virus. Man84 and its dimeric constructs display the best affinity and avidity reported to date for low-valency glycomimetics targeting CLRs. They are promising tools for competing with SARS-CoV-2 anchoring in the respiratory tract and have potential for other medical applications.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From diarylsulfides to diarylamines: new Ebola virus entry inhibitors with improved metabolic stability

  • Morales-Tenorio, Marcos
  • Lasala, Fátima
  • García-Rubia, Alfonso
  • Aledavood, Elnaz
  • Heung, Michelle
  • Olal, Catherine
  • Escudero-Pérez, Beatriz
  • Oquist, Paola
  • Canales, Ángeles
  • Alonso Martí, Covadonga
  • Martínez Gil, Ana
  • Muñoz-Fontela, César
  • Delgado, Rafael
  • Gil, Carmen
15 p.-7 fig.-4 tab.-1 graph. abst., The persistence of current outbreaks of Ebola virus (EBOV) disease and challenges in the production and administration of approved vaccines and treatments highlight the continuous exploration of new therapeutic alternatives. In this context, this work focuses on optimizing diarylsulfide hits previously identified as EBOV entry inhibitors. Structural modifications resulted in diarylamine derivatives, with confirmed antiviral activity against replicative EBOV and significantly improved metabolic stability compared to diarylsulfides. Using different techniques, the EBOV glycoprotein (EBOV-GP) was identified as the target of these compounds. Residue Y517GP2 is critical for biological activity, while T519GP2, E100GP1, and D522GP2 also contribute to ligand binding. Furthermore, the binding of the derivatives to EBOV-GP has been shown to destabilize the complex with the virus receptor NPC1. In short, a new family of diarylsulfides and diarylamines with antiviral activity against EBOV has been developed, and their mechanism of action has been deciphered, paving the way for future pharmaceutical development., The project leading to these results has received funding from “la Caixa” Foundation under the project code LCF/PR/HR19/52160012. This research was partially supported through ERA-NET-2021-862605 and cofounded by MICIU/AEI/10.13039/501100011033 and FEDER/UE (Grants PCI2021-121939 (C.A.), PID2021-122825OB (C.A.), PID2023-151109OB-I00 (A.C.) and PID2021-122223OB-I00 (C.G.)), Instituto de Salud Carlos III (CIBERINFEC, CIBERNED and FIS PI2100989), and the European Commission Project e-FabRIC: ID: 101137157, HORIZON-HLTH-2023-DISEASE-03-04 and Project Ebola PREP-TBOX, ID 101145709, and HORIZON-JU-GH-EDCTP3-2023-01 to RD. This research work was also funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI+ Salud Global). M.M.-T. holds a predoctoral FPU grant (FPU18/03493) from MICINN., Peer reviewed